Also found in: Wikipedia.


a monoclonal antibody against respiratory syncytial virus, used as a passive immunizing agent against infection with the virus in susceptible infants and children; administered intramuscularly.



Pharmacologic class: Monoclonal antibody

Therapeutic class: Immunologic agent

Pregnancy risk category C


Neutralizes and suppresses activity of syncytial virus in respiratory tract, inhibiting respiratory syncytial virus (RSV) replication


Injection: 50 mg, 100-mg vial

Indications and dosages

To prevent serious lower respiratory disease caused by RSV in high-risk children

Children: 15 mg/kg I.M. q month throughout RSV season


• Hypersensitivity to drug or its components


Use cautiously in:
• thrombocytopenia, coagulation disorders, established RSV infection.


Keep epinephrine 1:1,000 available in case anaphylaxis occurs. (However, drug isn't known to cause anaphylaxis.)
• Dilute in sterile water for injection. Gently swirl for 30 seconds to avoid foaming.
• Keep reconstituted solution at room temperature for at least 20 minutes before administering. Give within 6 hours of reconstitution.
• Inject I.M. into anterolateral thigh. Avoid gluteal injection, which may damage sciatic nerve.

Adverse reactions

CNS: nervousness, pain

EENT: conjunctivitis, otitis media, rhinitis, pharyngitis, sinusitis

GI: vomiting, diarrhea, gastroenteritis, oral moniliasis

Hematologic: anemia

Respiratory: upper respiratory tract infection, cough, wheezing, dyspnea, bronchiolitis, bronchitis, pneumonia, croup, asthma, apnea

Skin: rash, fungal dermatitis, eczema

Other: hernia, pain, fever, injection site reaction, viral infection, flulike symptoms, failure to thrive


Drug-diagnostic tests.Alanine aminotransferase, aspartate aminotransferase: increased levels

Hemoglobin: decreased level Immunological-based RSV diagnostic tests: interference, possibly leading to false-negative test results

Patient monitoring

Watch closely for signs and symptoms of anaphylaxis immediately after dosing.
• Assess for signs and symptoms of infection, particularly EENT and respiratory infection.
• Monitor liver function tests and CBC.
• Assess patient's weight and hydration status.

Patient teaching

• Tell parent that monthly injections are necessary during RSV season (November through April).
• Inform parent that drug may cause GI symptoms and failure to thrive. Provide dietary consultation as needed.

Caution parent that EENT and respiratory infections may follow administration. Advise parent to contact pre-scriber immediately if child has fever or other signs or symptoms of infection.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


/pal·i·viz·u·mab/ (pal″ĭ-viz´u-mab) a monoclonal antibody against respiratory syncytial virus (RSV); used as a passive immunizing agent in susceptible infants and children.


a monoclonal antibody.
indications It is used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients.
contraindications Use is prohibited in adults, in patients with cyanotic congenital heart disease, and in patients with known hypersensitivity to this drug.
adverse effects Adverse effects include nausea, vomiting, diarrhea, increased AST, upper respiratory infection, otitis media, rhinitis, pharyngitis, rash, and injection site reaction.


Synagis® Immunology A humanized monoclonal antibody used as prophylaxis against RSV infection Adverse effects Fever pneumonia, and injection site reactions. See Respiratory syncytical virus.
References in periodicals archive ?
Palivizumab immunoprophylaxis is the only available measure to prevent severe RSV disease.
Otuz ikinci gebelik haftasindan once dogan bebeklerin RSV enfeksiyonundan korunmasinda humanize bir monoklonal antikor olan palivizumab ile koruma onerilmektedir (12).
Palivizumab sadece respiratuvar sinsityal virusa (RSV) spesifik monoklonal bir antikordur.
The treatment, motavizumab, was designed to replace Synagis, also known as palivizumab, before it loses patent protection in 2015.
In a randomised, double-blind, placebo-controlled trial including 1 287 children with congenital heart disease (CHD) randomly assigned to receive 5-monthly intramuscular injections of 15 mg/kg palivizumab or placebo, palivizumab recipients had a 45% relative reduction in RSV hospitalisations (p=0.
However, there is effective passive immunization with a monoclonal antibody, palivizumab (Synagis).
Fomivirsen sodium for AIDS-related CMV (cytomegalovirus) retinitis and palivizumab for RSV (respiratory syncytial virus) complications will increase the fastest in demand among other new products.
44 - completely denatured alcohol absolute- Problem # 33 - Means of contrast- Task number from 15 to 32 and 34, 39, 40, 41, 42, 43, 50-54 - Other medicaments include Acylovir, Paracetamol, Propofol, POSACONAZOLE, Palivizumab, Omeprazole, albumin, antithrombin, Etanercept, Kaspofugina, Abelcet, Imatybin, Bridion, Interferon, Nivestim, Botulinum toxin, Caphosol, Curosurf, Sevofluran, Desfluran, Human Immunoglobulin, Modulen, Peptamen, Ferbini, PreNAN, NAN PRO, Mycafungina, Peginterferonum, deferasirox, AmBisome, etc.
Background: The aims of this study are to define the length of the respiratory syncytial virus (RSV) season throughout Florida and evaluate the American Academy of Pediatrics (AAP) guidelines on the administration of palivizumab in light of the Florida data.
The guidelines are based on the most recent research available in accordance with the FDA indication for palivizumab, a monoclonal antibody that has been shown to significantly decrease the severity of RSV in premature, at-risk infants.
Palivizumab (Synagis), a monoclonal IgG antibody preparation directed against the F glycoprotein of RSV, has the following advantages over RSV-IGIV: (1) the small required dose of palivizumab (15 mg/kg/dose) permits intramuscular injection, (2) the immunization schedule need not be altered after administration, (3) no fluid overload occurs, and (4) there is no possibility of transmission of blood-borne pathogens.